|1.84||-0.0600||-3.16%||Vol 2.33M||1Y Perf -88.97%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||0.07 3.76%|
|Target Price||55.43||Analyst Rating||Moderate Buy 2.00|
|Potential %||2.91K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 45.08|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||0.43||Earnings Rating||—|
|Market Cap||173.66M||Earnings Date||3rd Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.90|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.96M|
|Avg. Monthly Volume||2.41M|
|Avg. Quarterly Volume||2.22M|
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) stock closed at 1.84 per share at the end of the most recent trading day (a -3.16% change compared to the prior day closing price) with a volume of 2.33M shares and market capitalization of 173.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 54 people. Arcutis Biotherapeutics Inc. CEO is Todd Franklin Watanabe.
The one-year performance of Arcutis Biotherapeutics Inc. stock is -88.97%, while year-to-date (YTD) performance is -87.57%. ARQT stock has a five-year performance of %. Its 52-week range is between 1.77 and 18.04, which gives ARQT stock a 52-week price range ratio of 0.43%
Arcutis Biotherapeutics Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 3.38, a price-to-sale (PS) ratio of 1 216.88, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -69.37%, a ROC of -73.93% and a ROE of -98.07%. The company’s profit margin is -%, its EBITDA margin is -41 583.20%, and its revenue ttm is $725.00 Thousand , which makes it $0.01 revenue per share.
Of the last four earnings reports from Arcutis Biotherapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.90 for the next earnings report. Arcutis Biotherapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Arcutis Biotherapeutics Inc. is Moderate Buy (2), with a target price of $55.43, which is +2 912.50% compared to the current price. The earnings rating for Arcutis Biotherapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arcutis Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arcutis Biotherapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.37, ATR14 : 0.30, CCI20 : -98.43, Chaikin Money Flow : -0.30, MACD : -0.39, Money Flow Index : 62.32, ROC : -3.41, RSI : 30.52, STOCH (14,3) : 12.39, STOCH RSI : 0.51, UO : 33.25, Williams %R : -87.61), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arcutis Biotherapeutics Inc. in the last 12-months were: Burnett Patrick (Sold 5 682 shares of value $74 145 ), Burrows Scott (Sold 2 141 shares of value $33 866 ), David W. Osborne (Sold 690 shares of value $10 532 ), Howard G. Welgus (Option Excercise at a value of $57 135), Howard G. Welgus (Sold 34 000 shares of value $481 820 ), Kenneth Lock (Sold 831 shares of value $12 684 ), Life Sciences Viii, L.P. Frazier (Buy at a value of $200 000), Lock Kenneth (Sold 3 199 shares of value $50 483 ), Masaru Matsuda (Sold 1 434 shares of value $22 696 ), Matsuda Masaru (Sold 5 114 shares of value $40 635 ), Matthew Richard Moore (Sold 1 610 shares of value $25 481 ), Moore Matthew (Sold 1 610 shares of value $25 485 ), Osborne David (Sold 2 695 shares of value $42 536 ), Patricia A. Turney (Sold 831 shares of value $12 684 ), Patrick Burnett (Sold 4 077 shares of value $62 838 ), Scott L. Burrows (Sold 291 shares of value $4 442 ), Todd Franklin Watanabe (Sold 4 435 shares of value $71 182 ), Turney Patricia (Sold 3 199 shares of value $50 483 ), Watanabe Todd (Sold 12 250 shares of value $195 672 ), Welgus Howard (Sold 0 shares of value $-57 120 ), Welgus Howard (Sold 34 000 shares of value $481 780 )
Tue, 07 Nov 2023 21:17 GMT Arcutis Biotherapeutics (ARQT) was downgraded to a Hold Rating at JonesTrading- TipRanks. All rights reserved.
Fri, 07 Jul 2023 13:25 GMT Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.